As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing medicine, Zepbound, the Danish pharmaceutical behemoth Novo Nordisk A/S (NYSE:NVO ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

The list features 100 leading businesswomen from finance, tech, health care, telecom, retail, energy, and other industries.

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Noom will start offering smaller doses of compounded Wegovy (NVO), the blockbuster weight-loss drug, as the digital health ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have they changed positions in the annual IDEA Pharma Innovation Index, which ...

Lilly—a manufacturer of medicines like Mounjaro, Zepbound and Ebglyss—is considering purchasing 236 acres from Generation ...

Discover why the Invesco S&P 500 Top 50 ETF (XLG) is a strong buy with sector-leading stocks, outperformance, a low 0.2% ...